[HTML][HTML] Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
A Martin-Bastida, RJ Ward, R Newbould… - Scientific …, 2017 - pubmed.ncbi.nlm.nih.gov
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
A Martin-Bastida, RJ Ward, R Newbould… - Scientific …, 2017 - ui.adsabs.harvard.edu
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
A Martin-Bastida, RJ Ward, R Newbould, P Piccini… - Scientific Reports, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Parkinson's disease (PD) is associated with
increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron …
increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron …
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
A Martin-Bastida, RJ Ward, R Newbould, P Piccini… - Scientific …, 2017 - europepmc.org
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
[HTML][HTML] Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
A Martin-Bastida, RJ Ward, R Newbould… - Scientific …, 2017 - ncbi.nlm.nih.gov
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
A Martin-Bastida, RJ Ward, R Newbould, P Piccini… - Scientific …, 2017 - europepmc.org
Parkinson's disease (PD) is associated with increased iron levels in the substantia nigra
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …
(SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to …